192 related articles for article (PubMed ID: 15926762)
1. Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population.
Stephenson JJ; Barghout V; Kahler KH; Fernandes J; Beaulieu JF; Joo S; Boccuzzi SJ
Am J Manag Care; 2005 Apr; 11(1 Suppl):S35-42. PubMed ID: 15926762
[TBL] [Abstract][Full Text] [Related]
2. Budget impact of tegaserod on a managed care organization formulary.
Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
[TBL] [Abstract][Full Text] [Related]
3. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.
Kwong WJ; Diels J; Kavanagh S
Ann Pharmacother; 2010 Apr; 44(4):630-40. PubMed ID: 20197473
[TBL] [Abstract][Full Text] [Related]
4. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
5. Tegaserod treatment for IBS: a model of indirect costs.
Smith DG; Barghout V; Kahler KH
Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
7. Review article: tegaserod -- the global experience.
Chey WD
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
[TBL] [Abstract][Full Text] [Related]
8. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
10. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
11. [Tegaserod in treatment of women with irritable bowel syndrome].
Munck LK; Ainsworth MA
Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
[TBL] [Abstract][Full Text] [Related]
12. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC; Barghout V; McBurney CR; Niecko TE
Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
[TBL] [Abstract][Full Text] [Related]
13. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
[TBL] [Abstract][Full Text] [Related]
14. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
15. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal illness in managed care: healthcare utilization and costs.
Lim D; Farup C; Lawrence BJ; Sorrell L; Dubois RW; Zeldis JB
Am J Manag Care; 1997 Dec; 3(12):1859-72. PubMed ID: 10178475
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger C
Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
19. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population.
Hurley JS; Frost EJ; Trinkaus KM; Buatti MC; Emmett KE
Am J Manag Care; 1998 Dec; 4(12):1691-8. PubMed ID: 10339101
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and care of irritable bowel syndrome in a community-based population.
Yawn BP; Locke GR; Lydick E; Wollan PC; Bertram SL; Kurland MJ
Am J Manag Care; 2001 Jun; 7(6):585-92. PubMed ID: 11439732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
